Navigation Links
Declaring War on Severe Asthma-COPD Overlap Syndrome
Date:5/6/2013

FOLSOM, Calif., May 6, 2013 /PRNewswire-iReach/ -- War has been declared on Severe Asthma-COPD Overlap Syndrome (ACOS). It's tied in with recognition of World Asthma Day May 7, 2013.

The World Asthma Foundation (WAF) is leading the charge to raise awareness and to elevate the discussion about this highly prevalent but terribly underappreciated ACOS syndrome.

ACOS, which was formerly called "asthmatic bronchitis," is a commonly experienced, yet loosely defined clinical entity. It accounts for approximately 15 to 25 percent of the general population with obstructive airway diseases who experience more severe outcomes compared to asthma or COPD alone.

The prevalence of frequent exacerbations in ACOS is nearly two-and-a-half times higher than COPD and risk of severe exacerbations in ACOS is twice as high as COPD. However, standard treatment options are not as aggressive as needed to treat the asthma-COPD syndrome.

"ACOS is concerning because it's much worse in terms of exacerbations, or acute attacks of breathlessness, as compared to COPD." said Amir Zeki , MD, assistant professor of medicine pulmonary, critical, and sleep medicine at the Center for Comparative Respiratory Biology and Medicine at the University of California Davis School Of Medicine and World Asthma Foundation Board Member.

"We are entering a new era of public awareness of people living with chronic lung disease such as asthma and COPD," said Sam Louie , MD and professor of medicine, director of the UC Davis Asthma Network (UCAN), director of the UC Davis Reversible Obstructive Airway Disease (ROAD) Center, which serves adults and adolescents in Northern California who have difficult to control asthma, bronchiectasis and COPD.

"Our mission at UC Davis is to transform health care by integrating and provide quality patient care services these conditions, which promote patient education and safety, social networking, and to align our goals with national efforts to transform people's lives," Louie said. "But we can achieve success without recognizing the clear and present danger from not being aware of the Asthma-COPD Overlap syndrome."

"It really all begins with empathy." Louie said. "Empathy of healthcare providers for how asthma, COPD and ACOS patients suffer when they are given prescription drugs without education on an individual level. We have to ignite that empathy by increasing awareness and providing education."

The two physicians are board members of the World Asthma Foundation, which provides educational resources that inform patients, medical professionals and the general public about the latest clinical advances, management and treatment options for asthma disorders, including ACOS.

"People with asthma, COPD and ACOS deserve better," Louie said. "It requires that we all take responsibility, patients too, but physicians must take their empathy one step further and realize how reversible asthma, COPD and ACOS can be."

William Cullifer , executive director of the World Asthma Foundation, said, "This is a fascinating new development in the understanding of asthma and COPD and it's fantastic to be on the forefront of educating the public and the healthcare community about this issue."

Louie added, "When you get done taking care of the disease, you're taking care of people. We must fight indifference and the only way to do that is to get the word out that we all have much more to achieve together to empower patients with reversible obstructive airway diseases."

For more information visit: http://worldasthmafoundation.org

Media Contact: William Cullifer World Asthma Foundation, 916 790-1166, bill@worldasthmafoundation.org

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE World Asthma Foundation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Surveyed U.S. Pulmonologists Expect to Treat Nearly 50 Percent of Their Severe, Refractory Asthma Patients With a Biologic or Biosimilar Version of Xolair By the End of 2018
2. Defective Medicare Bidding Program For Medical Equipment Forces Severe Hardships On California Business Owners And Beneficiaries
3. Catabasis Initiates Phase 1 Trial of CAT-2003 for Treatment of Severe Hypertriglyceridemia
4. Sanofi US Offers a New Way to Say "Thank You" and Recognize the Unsung Heroes of Severe Allergy Awareness
5. Isis Pharmaceuticals Reports Clinical Data Showing Blunting of Severe Increases in CRP Following Endotoxin Challenge With ISIS-CRP Rx
6. Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohns Disease in the European Union
7. First U.S. Patients Treated in PneumRx RENEW Pivotal Study for Treatment of Severe Emphysema
8. Unilife Corporation Reschedules Release Of Quarterly Results And Earnings Call Due To Severe Weather In Northeastern U.S.
9. Lilly Supports Research to Determine What a Dogs Nose Knows About People with Diabetes and Severe Hypoglycemia
10. Albireo Receives Positive Opinion for Orphan Drug Designation for A4250 for Severe Liver Diseases
11. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... , Feb. 22, 2017 Henry ... an exclusive distribution agreement with Rijuven, which develops ... diagnostic device to medical practitioners. ... electrocardiogram (ECG) and heart sound signals, transmits real-time ... and offers cloud-based analysis to help physicians provide ...
(Date:2/22/2017)... Calif. , Feb. 22, 2017  Bioness, Inc., ... therapies, today announced the first series of successful StimRouter ... at Radboud University Medical Center (Nijmegen, Netherlands ... ( Cork, Ireland ), and Kliniek Park ... the successful launch continuing, Bioness plans to further support ...
(Date:2/22/2017)... , Feb. 22, 2017 Oncternal Therapeutics, ... for both rare and common malignancies, today announced ... financing. The company intends to use the proceeds ... TK216, and to advance preclinical development of a ... Cirmtuzumab is a first-in-class anti-ROR1 monoclonal antibody being ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... ... newest advanced absorption cannabidiol (CBD) serum, “NANOCALM 300” Microemulsified Hemp Extract. This ... instant absorption from the mouth into the bloodstream. Far outpacing the ...
(Date:2/22/2017)... ... 22, 2017 , ... The Centers for Medicare & Medicaid ... in Delaware, New Jersey, Pennsylvania and West Virginia prepare for and participate in ... Act of 2015 (MACRA). , This technical assistance, authorized and funded under ...
(Date:2/22/2017)... NJ (PRWEB) , ... February 22, 2017 , ... ... healthcare communications company, launched a new media platform connecting healthcare technology professionals and ... will be followed by a quarterly publication starting on March 1, announced Michael ...
(Date:2/22/2017)... ... February 22, 2017 , ... Pet obesity in the U.S. continued ... according to the Association for Pet Obesity Prevention (APOP). During the ninth annual survey, ... such as the benefits of corn and grains, value of raw and organic diets, ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... so many different solutions on the market, it is easy to start feeling ... Premier Locksmith offers a complimentary security consultation. , Home Security Hardware Choices, ...
Breaking Medicine News(10 mins):